Suppliers

Patheon Inc

Patheon Pharmaceuticals Services Inc

Patheon is a leading provider of contract development and commercial manufacturing (CDMO) services to the global pharmaceutical industry for a full array of solid and sterile dosage forms. Patheon, a DPx Holdings B.V. business unit, encompasses the combined CMO capabilities and pharmaceutical product development services (PDS), as well as the Biosolutions and Biologics (BIO) business.

Biologic Drug Substance Capabilities

From pre-clinical development to commercial supply, Patheon is an industry leader in the development and manufacture of mammalian cell culture drug substances. Patheon offers biotech and pharmaceutical companies the ability to pursue opportunities around the globe with a fully integrated network of facilities. These world-class cGMP sites feature USP and DSP processes and technologies that enable us to meet your preclinical, clinical and commercial milestones and goals for even your most challenging projects. With unmatched flexibility, Patheon gives you access to a breadth of options and technical expertise in biologic drug substance that will transform your expectations for yields, time to market and costs and that is supported by sterile manufacturing, including aseptic filling and lyophilization.
• Process and analytical development of mammalian cell culture drug substances
• Clinical and commercial cGMP manufacturing via fed-batch, perfusion and XD®
• cGMP and non-cGMP supply

Pharmaceutical Development Services

Patheon enables its customers to bring drug candidates from preclinical stages through to clinical trials, the NDA approval process and, if approved, commercial manufacturing. Patheon offers the full breadth of advanced scientific and preformulation services through to late development in solid and sterile dosage forms, as well as specialized capabilities in high potency, controlled/sustained release, and sterile manufacturing, including aseptic filling and lyophilization. Very few CDMOs can bring this big-picture perspective to building success into both solid and sterile pharmaceutical products. We give you access to a remarkably wide selection of formulation technologies.
• Conventional and specialized oral solid dose formats, including softgels and softgel technologies
• Liquid and lyophilized sterile products, including prefilled syringes and cartridges
• High potency products and controlled substances
• Solubility and bioavailability enhancement expertise

Commercial Manufacturing Capabilities

As the global leader in large-scale pharmaceutical manufacturing, Patheon offers extensive commercial capabilities and capacity for drug product manufacturing. We have a global network of twelve fully integrated world-class commercial scale facilities – all preapproved by international regulatory agencies, and all maintaining the highest standards of quality and service. We take pride in our steadfast reliability, unmatched regulatory track record but also in our spirit of innovation, as demonstrated by our introduction of the world’s first sterile backup supply service. Over the course of nearly 40 years Patheon has earned the trust of the most quality-conscious pharmaceutical companies by being able to provide exceptional service in:
• Large-scale capabilities and capacity at facilities around the world
• Wide variety of solid, sterile and softgel dose forms
• Award-winning technology transfers and scale-up
• Expertise in complex formulations, controlled substances and highly potent compounds
• Primary and secondary packaging

The company's integrated development and manufacturing network consists of more than 20 integrated locations around the world, including large-scale manufacturing facilities, API and fine chemicals development and manufacturing operations, biologics development and manufacturing sites and pharmaceutical development centers. For more information, please visit www.patheon.com​.

Related resource

Fast and Flexible – Early Phase Manufacturing

Fast and Flexible – Early Phase Manufacturing

Patheon Inc | 05-May-2014 | Case Study

Early-stage manufacturers of oral solid dosage forms need to be fast and flexible to generate development pathways that can cope with variable API characteristics...